The supplemental new drug application for the drug in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration, the company announced Tuesday.

该公司周二宣布，国家医疗产品管理局已批准该药物与化疗联合作为围手术期治疗的补充新药申请，以及随后作为辅助治疗的单药治疗，用于治疗可切除的IIIA-IIIB期癌症（NSCLC）成年患者。

Radical surgery in combination with chemotherapy is a way to prevent recurrence, but chemotherapy alone, as preoperative neoadjuvant or postoperative adjuvant therapy, has limited clinical benefits and can only raise patients' 5-year survival rate by approximately 5 percent.

根治性手术联合化疗是预防复发的一种方法，但单独化疗作为术前新辅助或术后辅助治疗，临床益处有限，只能将患者的5年生存率提高约5%。

In the vaccine field, GSK will continue to showcase its blockbuster products, including a shingles vaccine, which showed 100 percent protective efficacy in Chinese adults aged 50 and above as shown in the latest research data, and a bivalent HPV vaccine, the only HPV vaccine using the AS04 innovative adjuvant system.

在疫苗领域，葛兰素史克将继续展示其重磅产品，包括带状疱疹疫苗，如最新研究数据所示，该疫苗对50岁及以上的中国成年人显示出100%的保护效力，以及二价HPV疫苗，该疫苗是唯一使用AS04创新佐剂系统的HPV疫苗。

Chinese clinical-stage biotech Clover Biopharmaceuticals and Nasdaq-listed Dynavax Technologies Corp, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced on Wednesday a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).

CpG 1018 is the adjuvant used in an adult hepatitis B vaccine approved by the United States Food and Drug Administration and the European Commission.

It will produce and provide to GSK various types of HPV vaccine antigens, which will be combined with GSK's patented adjuvant to develop new HPV vaccines for worldwide commercialization, including in Europe and the United States.

This vaccine will combine the innovative antigen detection method developed by Prof Xia Ningshao's team at Xiamen University, with GSK's proprietary adjuvant AS04, which leverages this antigen technology.

It will produce and provide to GSK various types of HPV vaccine antigens, which will then be combined with GSK's patented AS04 adjuvant to develop new HPV vaccines for worldwide commercialization, including in Europe and the United States.

The newly approved indication, for patients suffering from locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, is the first in a solid tumor indication.